Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!

CAR-T cell therapy for cancer: The patient's in the process

CAR-T cell therapy for cancer: The patient's in the process

Around 1,000 people are diagnosed with cancer every day in the UK. Fortunately, outcomes continue to improve, with around half of those diagnosed...

Read More
Engineering Challenges in Designing Pharmaceutical Isolators

Engineering Challenges in Designing Pharmaceutical Isolators

In this latest blog, James Lau, one of 3P’s Project Engineers, tells us all about barrier systems across a range of areas. Specifically taking a...

Read More
Formulation Freedom in Clinical Development: Why Fill2Weight Matters

Formulation Freedom in Clinical Development: Why Fill2Weight Matters

In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation...

Read More